Match tier
Listed
Presence
Current · Arkansas
Last published
2025
Sources
OpenAlex · ORCID
Refreshed
2026-08-15
P
Phuc Tran
Undergraduate Researcher
Also affiliated: Johns Hopkins University (2011); University of Alberta (2025)
Faculty Researcher
6 h-index
12 pubs
165 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Phuc Tran's research focuses on drug discovery and the development of novel therapeutic agents, particularly in the area of oncology. Tran has investigated the structure-activity relationships of various molecular compounds, including pyrimidine derivatives and imidazo[1,2-a]pyridine derivatives, for their potential to inhibit specific protein kinases implicated in cancer, such as RET and FLT3. Publications also detail work on new cereblon ligands for targeted protein degradation and the discovery of orally active selective aurora kinase B inhibitors. Further research areas include exploring bifunctional inhibitors for virus-associated lymphomas and understanding the mechanisms of immune evasion in melanoma. Tran collaborates with researchers at the University of Arkansas for Medical Sciences, including Yuet-Kin Leung and Brendan Frett, with whom multiple publications are shared.
Metrics
- h-index: 6
- Publications: 12
- Citations: 165
Selected Publications
-
Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor (2025)
-
CD36-mediated endocytosis of proteolysis-targeting chimeras (2025)
-
Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation (2024)
-
An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L (2023)
-
Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas (2023)
-
Delivery of Oligonucleotides: Efficiency with Lipid Conjugation and Clinical Outcome (2022)
-
3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O’PROTAC (2022)
-
Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose (2022)
-
Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology (2021)
-
Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors (2021)
-
Mi-2β-targeted inhibition induces immunotherapy response in melanoma (2020)
Collaboration Network
Top Collaborators
Hongyu Li
The University of Texas Health Science Center at San Antonio (US)
9 shared publications
- Delivery of Oligonucleotides: Efficiency with Lipid Conjugation and Clinical Outcome
- CD36-mediated endocytosis of proteolysis-targeting chimeras
- 3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O’PROTAC
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas
Showing 5 of 9 shared publications
Yuet‐Kin Leung
University of Arkansas for Medical Sciences
4 shared publications
In database
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
- Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
- Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology
Brendan Frett
University of Arkansas for Medical Sciences
4 shared publications
In database
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
- Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
- Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology
Wei Yan
University of Arkansas for Medical Sciences (US)
4 shared publications
- CD36-mediated endocytosis of proteolysis-targeting chimeras
- 3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O’PROTAC
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Anupreet Kharbanda
University of Arkansas for Medical Sciences
3 shared publications
In database
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
- Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology
Lingtian Zhang
University of Arkansas for Medical Sciences (US)
3 shared publications
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
- Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology
Xiuqi Wang
University of Arkansas for Medical Sciences
3 shared publications
In database
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Zhenyu Wang
The University of Texas Health Science Center at San Antonio (US)
3 shared publications
- 3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O’PROTAC
- Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Marialuisa Moccia
University of Naples Federico II (IT)
2 shared publications
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Francesca Carlomagno
University of Naples Federico II (IT)
2 shared publications
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Jingwei Shao
University of Arkansas for Medical Sciences
2 shared publications
In database
- CD36-mediated endocytosis of proteolysis-targeting chimeras
- 3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O’PROTAC
Tsigereda Weldemichael
University of Arkansas for Medical Sciences
2 shared publications
In database
- Delivery of Oligonucleotides: Efficiency with Lipid Conjugation and Clinical Outcome
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
Jungang Chen
Winthrop Rockefeller Foundation (US)
2 shared publications
- CD36-mediated endocytosis of proteolysis-targeting chimeras
- Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas
Zhiqiang Qin
Winthrop Rockefeller Foundation (US)
2 shared publications
- CD36-mediated endocytosis of proteolysis-targeting chimeras
- Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas
Gunaganti Naresh
University of Arkansas for Medical Sciences
2 shared publications
In database
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Similar Researchers
Based on overlapping research topics
Baha’a Jabali
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Drug Discovery
Protein Kinase Inhibitors
Anupreet Kharbanda
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Drug Discovery
Protein Kinase Inhibitors
Brendan Frett
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Protein Kinase Inhibitors
Molecular Biology Techniques and Applications
Yuntao Dai
University of Arkansas at Fayetteville
Cancer Treatment and Pharmacology
Molecular Biology Techniques and Applications
Cancer-related molecular mechanisms research
Fabricio Medina‐ Bolivar
Arkansas State University
Cancer Treatment and Pharmacology
Molecular Biology Techniques and Applications
Cancer-related molecular mechanisms research
Katie R. Ryan
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Protein Kinase Inhibitors
Molecular Biology Techniques and Applications